AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The
Company discovers, develops, and commercializes advanced therapies.
AbbVie's portfolio of products include a line of adult and pediatric
pharmaceuticals, which includes HUMIRA, metabolics/hormones products,
virology products, endocrinology products, dyslipidemia products and
other products. AbbVie products are used to treat rheumatoid arthritis,
psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic
fibrosis complications, low testosterone, thyroid disease, Parkinson's
disease and complications associated with chronic kidney disease, among
other indications. In October 2012, AbbVie initiated a comprehensive
Phase III program for hepatitis C virus (HCV) genotype one.
Abbott (NYSE: ABT)
is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical
products, including nutritionals, devices and diagnostics. The company
employs approximately 91,000 people and markets its products in more
than 130 countries.
Abbott Park, Illinois (NYSE: ABT)
— Abbott announced today that the French Autorité des marchés
financiers ("AMF") has approved the prospectus filed by AbbVie Inc., its
research-based pharmaceuticals business, for admission of AbbVie Inc.'s
common stock to listing and trading on the Professional Segment of NYSE
Euronext Paris ("Euronext"), and has granted visa number 12-599, dated
Dec. 14, 2012, on the prospectus (the "Prospectus"). The attention of
investors is drawn to the risk factors described in the Prospectus.
On Nov. 28, 2012, Abbott's board of directors approved the separation
of AbbVie, and declared a special dividend distribution of one share of
AbbVie common stock for each Abbott common share outstanding as of the
close of business on Dec. 12, 2012, the record date for the
distribution. Abbott expects the special dividend of AbbVie stock will
be distributed on Jan. 1, 2013.
On Dec. 14, 2012, Euronext approved AbbVie Inc.’s application for
listing and trading of its Common Stock on Euronext.
"As-if-and-when-issued" trading of AbbVie common stock is expected to
begin on Euronext on Dec. 20, 2012. AbbVie Inc. common stock will trade
on Euronext under the symbol "ABBV" and be denominated in Euros.
"As-if-and-when-issued" trading of AbbVie common stock will continue
on Euronext until Abbott pays the special dividend distribution of
AbbVie common stock on Jan. 1, 2013. AbbVie "as-if-and-when-issued"
trades on Euronext will settle after Jan. 1, 2013, with shares of AbbVie
as a standalone company.
AbbVie's common stock is listed on the New York Stock Exchange, under
the symbol "ABBV.WI" for "when issued" trading until Dec. 31, 2012, and
"ABBV" for "regular-way" trading beginning Jan. 2, 2013. AbbVie also
intends to list its common stock on the Chicago Stock Exchange and the
SIX Swiss Exchange.
Copies of the Prospectus may be obtained free of charge from AbbVie
Inc. at 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A.,
from its paying agent, BNP Paribas Securities Services (Postal
address: 3, rue d'Antin, 75002, France), and on the website of the AMF
(www.amf-france.org). Until Dec. 31, 2012, the Prospectus will be
available on the website of Abbott Laboratories (www.abbott.com).
Beginning Jan. 1, 2013, AbbVie Inc. will maintain an Internet site at
www.abbvie.com, where the Prospectus will be available.
Abbott has four core businesses—all focused
on advancing innovations that provide better options and outcomes for
people in their pursuit of healthy lives.
1-DIAGNOSTICS: PIONEERING MEDICAL DIAGNOSTICS
Our innovative instrument systems and tests help monitor a range of
health conditions with speed, accuracy and efficiency. From automated
immunodiagnostics systems and blood analyzers to sophisticated molecular
diagnostics and point-of-care devices, our technologies provide health
care professionals with information they need to make the best treatment decisions.
2-DEVICES: BETTER OPTIONS AND IMPROVED OUTCOMES
Less-invasive solutions for vascular procedures; fast, accurate blood
glucose meters; and advanced laser-vision correction technologies—our
advanced medical device technologies are designed to enable people to
return to their everyday lives faster and healthier.
3-NUTRITION: WORLDWIDE LEADER IN NUTRITION
We offer science-based nutrition products for every stage of life -
from infant and pediatric to adult healthy living and therapeutic
nutrition. Our products include leading consumer brands like Similac,
Ensure, Glucerna, PediaSure, EAS and ZonePerfect - as well as specialty
products that help meet the nutritional needs of people with a variety
of health conditions, such as cancer, diabetes, kidney disease and
osteoporosis.
4-PHARMACEUTICALS: LOCALIZED INNOVATION
We offer high-quality, affordable and trusted branded generic
medicines to help treat some of the most pervasive and persistent health
conditions around the world. Through packaging enhancements, new
formulations and innovative delivery methods, we tailor our offerings to
address regional health needs and provide access to some of the most
trusted and proven medicines to those who need them most.
Diversity is a wonderful source of strength. Abbott draws on our
diversity of expertise, geographies and technologies to spur innovation
that addresses important health needs at every stage of life.
Diagnostics
Diagnosing disease to help patients and physicians make the right treatment decisions.
View Products
Vascular
Transforming the treatment of cardiac and vascular disease.
View Products
Diabetes Care
Developing next-generation meters for breakthrough diabetes care.
View Products
Vision Technologies
Advancing the science of vision, from daily eye care to LASIK.
View Products
Nutrition
Pioneering nutrition solutions for every stage of life.
View Products
Pharmaceuticals
Trusted brands, innovative packaging and new delivery solutions to meet regional needs worldwide.
View Products
Animal Health
A name you can trust in advancing veterinary care.
View Products
No comments:
Post a Comment